期刊文献+

以Celecoxib为基础的联合方案对宫颈癌细胞抑制作用的研究 被引量:2

Study of Inhibiting Effects of Celecoxib-based Combination on Human Cervical Cancer Hela Cell Line
暂未订购
导出
摘要 目的:探讨环氧化酶-2(cox-2)抑制剂Celecoxib与化疗药顺铂(DDP)联合应用对人宫颈癌Hela细胞的作用及机制。方法:用免疫细胞化学SP法检测Hela细胞cox-2蛋白表达后,将Celecoxib、DDP单独或联合处理Hela细胞,用MTT法检测细胞增殖的抑制率,流式细胞仪检测细胞周期及凋亡。结果:Celecoxib可下调Hela细胞cox-2蛋白表达,抑制其增殖作用呈浓度和时间依赖性。在一定浓度范围内DDP也抑制Hela细胞生长,作用呈量效关系。Celecoxib与DDP联合应用后抗增殖作用较单一用药显著增强(P<0.05),DDP浓度≥1 mg/L时两者有协同或相加作用。Celecoxib及DDP均可有效诱导Hela细胞凋亡,联用凋亡率明显增加并出现G0-G1期细胞阻滞。结论:Celecoxib与DDP联用可通过抑制增殖、诱导细胞凋亡和细胞周期阻滞对Hela细胞有协同抗肿瘤效应,提示两者联合可能在宫颈癌临床治疗上具有潜在价值。 Objective: To investigate the effects of cyclooxygenase-2(cox-2) selective inhibitor, Celecoxib,combined with Cisplatin(DDP) on human cervical cancer Hela cell line and the possible mechanism. Methods: Cox-2 protein expression was detected by immunocytochemistry using isozyme selective antibodies. After treatment of Hela cells with Celecoxib,DDP or combination of both,the inhibitory rate of cells was measured by methabenzthiazuron(MTT) assay,cell cycle and apoptosis were analyzed by flow cytometry. Results: Celecoxib down-regulated the cox-2 protein expression of Hela cells and inhibited the cell proliferation in a concentration-dependent and time-dependent manner. DDP could inhibit the growth of cells in a dose-dependent manner too. When Celecoxib and DDP(≥1 mg/L) were combined, the inhibitory effect was remarkable enhanced in a synergistic or additive pattern(P〈0.05). Celecoxib(120 μmol/L) and DDP(2.5 mg/L) could respectively induce the apoptosis of Hela cells and cause G0-G1 cell cycle arrest, and this effect of apoptosis induction was increased when combinated Celecoxib with DDP. Conclusion: Celecoxib combined with DDP shows synergistic anti-tumor effects by enhancement of growth inhibition and apoptosis induction in Hela cell line, which indicate this combination may have a potential value in cervical cancer therapy.
出处 《武汉大学学报(医学版)》 CAS 2006年第1期47-50,115,i0003,共6页 Medical Journal of Wuhan University
关键词 CELECOXIB 宫颈癌HELA细胞 顺铂 Celecoxib Cervical Neoplasms Hela cell line Cisplatin
  • 相关文献

参考文献1

二级参考文献24

共引文献49

同被引文献40

  • 1高晓会,于世英,许三鹏,袁响林,徐姣珍.Celecoxib在人癌裸鼠移植瘤抗癌与放射增敏的作用机制研究[J].肿瘤防治研究,2005,32(1):4-7. 被引量:6
  • 2万珍玲,刘保安.环氧化酶-2抑制剂的放射增敏作用及研究进展[J].国外医学(临床放射学分册),2006,29(3):213-216. 被引量:2
  • 3拉莱·苏祖克.不同民族妇女中2727例子子宫颈癌的统计分析.新疆医学院学报,1990,(6):47-47.
  • 4Christiane JB, Matthew TH, Darren WD, et al. Epidermal growth factor receptor blockade with C225 plus gemcitahine results in regression of human pancreatic carcinoma growing orthotopieally in nude mice by antiangiogenic mechanisms[J]. Clin Cancer Res ,2000,6(5) ,, 1 936 - 1 948,
  • 5Inoue kJ, slaton JW, Perrotte P, et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma[J]. Clin cancer Res,2000,6:4 874-4 884.
  • 6Huang SM, Book JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck[J]. Cancer Res , 1999,59 (4) : 1 935 - 1 940.
  • 7Ciardiello F, Bianco R, miano V, et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225 [J]. Clin Cancer Res, 1999,5(4) :909- 916.
  • 8Aboud-pirak E, Hurwitz E, Pirak ME, et al. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice[J]. Natl Cancer Inst, 1988,80:1 605-1 611.
  • 9Baselga J, Norton L, Masui H, et al. Antitumore, effect of doxorubicin in combinition with anti-epidermal growth factor receptor monoclonal antibodies [J]. Natl Cancer Inst, 1993, 85:1 327-1 333.
  • 10Fan Z, baselga J, Masui H, et al. Antitumore effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts[J].Cancer Res, 1993,53:4 637 - 4 642.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部